Ernexa Therapeutics (NASDAQ:ERNA) Posts Earnings Results, Misses Expectations By $5.00 EPS

Ernexa Therapeutics (NASDAQ:ERNA) issued its earnings results on Monday. The company reported ($6.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.95) by ($5.00), FiscalAI reports.

Ernexa Therapeutics Stock Down 4.2%

NASDAQ:ERNA traded down $0.32 during mid-day trading on Monday, reaching $7.21. The company’s stock had a trading volume of 483,898 shares, compared to its average volume of 912,916. Ernexa Therapeutics has a 1 year low of $3.18 and a 1 year high of $100.46. The stock has a fifty day moving average of $5.89 and a 200-day moving average of $21.13. The firm has a market capitalization of $8.44 million, a PE ratio of -0.10 and a beta of 1.88.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ERNA. Brookline Capital Markets began coverage on shares of Ernexa Therapeutics in a research note on Thursday. They set a “buy” rating and a $30.00 target price for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Tuesday, April 21st. Finally, Wall Street Zen raised shares of Ernexa Therapeutics to a “hold” rating in a research note on Saturday. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $30.00.

Institutional Trading of Ernexa Therapeutics

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP acquired a new position in Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. 70.55% of the stock is owned by institutional investors.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.